• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   Açık Erişim Ana Sayfası
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • Öğe Göster
  •   Açık Erişim Ana Sayfası
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations

Yazar
Dunn-Galvin, Audrey
Price, Oliver J.
Akdis, Mubeccel
Khaitov, Musa
Alvarez-Perea, Alberto
Alvaro-Lozano, Montserrat
Atanaskovic-Markovic, Marina
Backer, Vibeke
Barbaud, Annick
Bavbek, Sevim
de Blay, Frederic
Bonini, Matteo
van Boven, Job F. M.
Brockow, Knut
Cazzola, Mario
Fernandez-Rivas, Montserrat
Rogala, Barbara
Romano, Antonino
Santos, Alexandra
Skypala, Isabel
Smolinska, Sylwia
Sokolowska, Milena
Sturm, Gunter
Vultaggio, Alessandra
Walusiak-Skorupa, Jolanta
Worm, Margitta
Palmer, Elizabeth
Shamji, Mohamed H.
Bonini, Sergio
Moreira, Andre
van Ree, Ronald
Sediva, Ana
Jutel, Marek
Torres, Maria J.
Palomares, Oscar
Akdis, Cezmi A.
Eiwegger, Thomas
Untersmayr, Eva
Barber, Domingo
Zemelka-Wiacek, Magdalena
Kosowska, Anna
Vieths, Stefan
Mahler, Vera
Canonica, Walter G.
Nadeau, Kari
Agache, Ioana
Chatzipetrou, Alexia
Chivato, Tomas
Cianferoni, Antonella
Corren, Jonathan
Cristoph-Caubet, Jean
Ebisawa, Motohiro
Firinu, Davide
Gawlik, Radoslaw
Gelincik, Asli
del Giacco, Stefano
Mortz, Charlotte G.
Hoffmann, Hans Jurgen
Hoffmann-Sommergruber, Karin
Klimek, Ludger
Knol, Edward
Lauerma, Antti
de Llano, Luis Perez
Matucci, Andrea
Meyer, Rosan
Morita, Hideaki
Patil, Sarita U.
Pfaar, Oliver
Popescu, Florin-Dan
del Pozo, Victoria
Üst veri
Tüm öğe kaydını göster
Özet
Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.
Bağlantı
http://hdl.handle.net/20.500.12627/183622
https://doi.org/10.1111/all.15252
Koleksiyonlar
  • Makale [92796]

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
İletişim | Geri Bildirim
Theme by 
Atmire NV
 

 


Hakkımızda
Açık Erişim PolitikasıVeri Giriş Rehberleriİletişim
sherpa/romeo
Dergi Adı/ISSN || Yayıncı

Exact phrase only All keywords Any

BaşlıkbaşlayaniçerenISSN

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTürlere GöreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTürlere Göre

Hesabım

GirişKayıt

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
İletişim | Geri Bildirim
Theme by 
Atmire NV